Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Prothena Corp
(NQ:
PRTA
)
20.87
+0.31 (+1.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Prothena Corp
< Previous
1
2
Next >
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
April 15, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in Upcoming Healthcare Conferences
March 05, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Appoints David Ford to Newly Created Chief People Officer Position
March 04, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
February 21, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
February 15, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
February 08, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
January 08, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Third Quarter 2023 Financial Results on November 2
October 26, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in Upcoming Healthcare Conferences
August 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Second Quarter 2023 Financial Results on August 3
July 27, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
July 17, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
July 11, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
July 10, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
June 27, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in Jefferies 2023 Healthcare Conference
June 02, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
May 16, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report First Quarter 2023 Financial Results on May 4
April 27, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in 2023 Bank of America Healthcare Conference
April 24, 2023
From
Prothena Corporation plc
Via
Business Wire
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
April 13, 2023
From
Walgreens
Via
Business Wire
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
March 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in Stifel 2023 Virtual CNS Days
March 21, 2023
From
Prothena Corporation plc
Via
Business Wire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Exposures
COVID-19
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
March 14, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
February 23, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 16, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
January 31, 2023
From
Prothena Corporation plc
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.